Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Quadrivalent meningococcal conjugate vaccines

Registered for use in people aged ≥2 months.

MenACWY-CRM — quadrivalent meningococcal (serogroups A, C, W-135, Y)–CRM197 conjugate vaccine

Lyophilised powder containing serogroup A in a monodose vial with a pre-filled syringe or vial containing serogroups C, W-135 and Y in saline suspension.

Each 0.5 mL reconstituted dose contains:

  • 10 µg meningococcal polysaccharide serogroup A conjugated to 16.7–33.3 µg Corynebacterium diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup C conjugated to 7.1–12.5 µg C. diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup W-135 conjugated to 3.3–8.3 µg C. diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup Y conjugated to 5.6–10 µg C. diphtheriae CRM197 protein

Also contains traces of:

  • sucrose
  • natural rubber

For full details, refer to the product information and consumer medicine information sheets for Menveo vaccine available on the TGA website.

Previous

Menitorix

Next

Mérieux Inactivated Rabies Vaccine

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018